Khoản tài trợEuropean Commission

Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Về cơ hội này

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities; Researchers, physicians, innovators [1] , startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals fro…

Nguồn

Thông tin này đến từ ec.europa.eu. Quý vị vui lòng kiểm tra điều kiện và hạn chót tại đó trước khi nộp hồ sơ.